Minoryx Press Release
2021-01-27

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from…
read more
Minoryx Press Release
2020-12-18

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows…
read more
Minoryx Press Release
2020-11-16

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone…
read more
Minoryx Press Release
2020-11-02

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

European Investment Bank provides Minoryx…
read more
Minoryx Press Release
2020-09-23

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Minoryx Therapeutics and Sperogenix Therapeutics…
read more
Minoryx News article
2020-02-18

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news
read more
Minoryx Press Release
2020-01-09

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Minoryx Therapeutics receives US FDA…
read more
Minoryx Press Release
2019-11-13

Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

Minoryx Therapeutics receives Orphan Drug…
read more
Minoryx Press Release
2019-10-17

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics receives FDA Orphan…
read more
Minoryx News article
2019-10-09

Minoryx: Un axe Espagne-Belgique pour sauter la barrière

Minoryx News Article: Un axe…
read more